COMPliance With Avonex® PS in Patients With Relapsing-Remitting MS
COMPASS
1 other identifier
observational
1,000
1 country
1
Brief Summary
A phase IV, observational, survey-based study to measure compliance with Avonex® PS therapy in patients with Relapsing-Remitting Multiple Sclerosis, and to compare persistence on therapy 22 months after initial prescription of AVONEX® PS between patients enrolled in the current MS AllianceTM program versus patients enrolled in this program prior to October 2007.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2008
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2008
CompletedFirst Submitted
Initial submission to the registry
May 8, 2008
CompletedFirst Posted
Study publicly available on registry
May 12, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2011
CompletedJanuary 30, 2012
January 1, 2012
3.6 years
May 8, 2008
January 26, 2012
Conditions
Outcome Measures
Primary Outcomes (2)
Compliance with therapy in the prospective arm
Week 7-10 and Week 80-83
Persistence on therapy between prospective and retrospective arms
22 months
Secondary Outcomes (1)
Patients' satisfaction with new MSA program
Week 7-10 and Week 80-83
Study Arms (2)
Prospective
500 patients who will be enrolled in the MS Alliance program will be consented to participate in this study.
Retrospective
500 patient chart reviews will be completed for patients who were enrolled in the MS Alliance program between two (2) to three (3) years ago.
Eligibility Criteria
Patients enrolled in the MS AllianceTM program
You may qualify if:
- Diagnosed with Relapsing Remitting Multiple Sclerosis (RRMS)
- Prescription of AVONEX® PS (prefilled syringes)
- Enrolment in the MS AllianceTM program
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Biogenlead
Study Sites (1)
University Hospital, London Health Sciences Centre
London, Ontario, Canada
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
May 8, 2008
First Posted
May 12, 2008
Study Start
May 1, 2008
Primary Completion
December 1, 2011
Study Completion
December 1, 2011
Last Updated
January 30, 2012
Record last verified: 2012-01